Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

NEO Biotech Stock Files Patent for Substance & Behavioral Addiction Treatment

Stockhouse Editorial
1 Comment| February 18, 2022

{{labelSign}}  Favorites
{{errorMessage}}

A biotechnology company, researching, developing, and delivering psychedelic therapeutics to better treat addiction announced this week that the team filed a patent application for a new chemical series of entactogen-like molecules. Entactogen-like molecules are a class of psychoactive substances that produce distinctive emotional and social effects.

Awakn Life Sciences Corp. (NEO: AWKN, Forum) believes has great potential to treat both substance and behavioural addictions. The company’s patent application covers the new chemical series, fulfils another significant step forward in the development of next generation entactogens and provides a key milestone in Awakn’s drug discovery program.

The company’s Chief Research Officer, Professor David Nutt commented in a news release that this novel entactogen-like molecules build on the company’s other recent filings to establish a strong pipeline of Novel Chemical Entities.

“These molecules have the potential to revolutionize the treatment of addiction by delivering improved efficacy in a shorter treatment time. Our aim is to treat addiction patients, more rapidly, effectively, and safely than has been possible to date.”

Awakn and its research partner, Evotec, have used a combined Artificial Intelligence / Medicinal Chemistry approach to identify initial hits. A number of these hits were verified using a set of in vitro screening and ADMET assays leading to the identification of multiple patentable series.



{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today